Vir Biotechnology Files 8-K

TL;DR

Vir Bio filed a routine 8-K, no major news.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on June 26, 2024, to report other events and financial statements/exhibits. The filing does not detail specific transactions or events beyond its routine reporting nature.

Why It Matters

This 8-K filing indicates routine corporate reporting by Vir Biotechnology, Inc. to the SEC, without disclosing specific material events.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, not indicating any specific negative or positive material changes.

Key Players & Entities

• Vir Biotechnology, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 001-39083 (company_id) — Commission File Number
• 81-2730369 (company_id) — IRS Employer Identification No.
• 1800 Owens Street, Suite 900 (address) — Principal executive offices
• San Francisco, California 94158 (address) — Principal executive offices
• 415-906-4324 (phone_number) — Registrant's telephone number
• June 26, 2024 (date) — Date of earliest event reported

FAQ

From the Filing

0001193125-24-168554.txt : 20240626 0001193125-24-168554.hdr.sgml : 20240626 20240626081529 ACCESSION NUMBER: 0001193125-24-168554 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240626 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240626 DATE AS OF CHANGE: 20240626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 241070679 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 d835539d8k.htm 8-K 8-K false 0001706431 0001706431 2024-06-26 2024-06-26     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024     Vir Biotechnology, Inc. (Exact name of registrant as specified in its charter)       Delaware   001-39083   81-2730369 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of principal executive offices, including zip code) (415) 906-4324 (Registrant’s telephone number, including area code)   (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value   VIR   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On June 26, 2024, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has cleared its investigational new drug application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection (the “Fast Track Designation”). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. Forward-Looking Statements This disclosure, including the press re